Bank of America
NRXPW

Bank of America’s NRX Pharmaceuticals Warrant NRXPW Stock Holding History

Bank of America’s Portfolio NRXPW Stock Details NRXPW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-95
Closed -$4 – 8333
2024
Q3 		$4 Hold
95
– – ﹤0.01% 8095
2024
Q2 		$6 Buy
+95
New +$12 ﹤0.01% 8118
2023
Q4 		– Sell
-600
Closed -$48 – 8158
2023
Q3 		$48 Buy
+600
New +$94 ﹤0.01% 7511
2022
Q2 		– Sell
-200
Closed – – 8262
2022
Q1 		$0 Buy
+200
New +$295 ﹤0.01% 8594

Other funds holding NRXPW

Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.66% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Bank of America's NRXPW Position: Q4 2024 in Review

Bank of America sold out of NRX Pharmaceuticals Warrant (NRXPW) in Q4 2024, closing a stake of 95 shares — an estimated $4 sold.

Bank of America first reported a position in NRXPW in Q1 2022 and held it in 4 quarters. The position peaked at $48 in Q3 2023. 5 funds tracked by Wall St. Rank hold NRXPW as of Q4 2024.

  • Bank of America reported no remaining NRX Pharmaceuticals Warrant position as of Q4 2024 after selling out during the quarter.
  • Bank of America sold 95 NRX Pharmaceuticals Warrant shares in Q4 2024, an estimated $4.
  • Bank of America first reported a position in NRX Pharmaceuticals Warrant in Q1 2022 and held it in 4 quarters.
  • Bank of America's NRX Pharmaceuticals Warrant position peaked at $48 in Q3 2023.
  • 5 funds tracked by Wall St. Rank held NRX Pharmaceuticals Warrant as of Q4 2024.

Based on Bank of America's 13F filing for Q4 2024, filed 14 Feb 2025.